Sunday, April 5, 2020
The New England Science Symposium (NESS), established in 2002, provides a forum for postdoctoral fellows; medical, dental and graduate students; post-baccalaureates; college and community college students (particularly for African-American, Hispanic/Latino and American Indian/Alaska Native individuals) to share their biomedical and health-related research activities through oral or poster presentations, to engage in discussions related to career development in the sciences, to exchange ideas and to expand their professional networks.
Awards for outstanding oral and poster presentations in various disciplines and categories are: Ruth and William Silen, M.D. Awards, Dana-Farber/Harvard Cancer Center Awards, Vertex Postdoctoral Awards, Beth Israel Deaconess Medical Center Department of Neonatology Award, Stem Cell and Regenerative Medicine Award, American Cancer Society Awards, and Predicine Translational Research Award.
For description of the awards and list of award winners, please click here.
Harvard Medical School
Minority Faculty Development Program (MFDP)
The Minority Faculty Development Program (Established 1990) of the Office for Diversity Inclusion and Community Partnership (Established 2002; originally named Faculty Development and Diversity) sponsors programs for the development of Harvard Medical School faculty and trainees, with an emphasis on mentoring and leadership, as well as programs that are designed to reach out to the pre-college, college, graduate and postdoctoral populations with the goal of bringing outstanding students from groups underrepresented in medicine into the biomedical science pipeline.
Biomedical Science Careers Program (BSCP)
BSCP was founded in 1991 by MFDP in collaboration with the Massachusetts Medical Society and the New England Board of Higher Education to identify, inform, support and provide mentoring for academically outstanding minority students and fellows ranging from high school to postdoctoral level.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. They discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
For more information please contact:
Program Coordinator - New England Science Symposium
Harvard Medical School
Hollie Borek DeSilva
Biomedical Science Careers Program